Cover Image
市場調查報告書

癌症免疫療法的各種契約趨勢

Deal Trends in Immuno-oncology

出版商 IMS World Publications Ltd. 商品編碼 364581
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫療法的各種契約趨勢 Deal Trends in Immuno-oncology
出版日期: 2016年02月28日 內容資訊: 英文
簡介

本報告提供癌症免疫治療藥相關的M&A調查,業務聯盟等企業間的各種交易、契約趨勢,癌症免疫治療藥的市場概要,目前治療方法,開發後期主要的產品,各種交易、契約最活躍的經營者,各開發階段、類型契約的契約數量及契約額等趨勢彙整。

摘要整理

第1章 市場概要

  • 癌症免疫療法的市場
  • 目前治療方法
  • 開發後期的主要產品
  • 市場分析
  • 主要企業
  • 摘要

第2章 癌症免疫療法:整體趨勢

  • 各種契約的強度

第3章 M&A契約

  • M&A契約趨勢
  • M&A契約額

第4章 聯盟契約

  • 聯盟契約趨勢
  • 聯盟契約:整體契約額
  • 聯盟契約:各開發階段
  • 聯盟契約:各類型契約
  • 聯盟契約:各產品類型
  • 聯合治療

第5章 企業分析

  • 契約最活躍的經營者
  • 企業的契約額分析

第6章 展望

附錄

圖表

目錄

Overview

The Deal Trends in Immuno-oncology report from IMS PharmaDeals, analyses immuno-oncology deals from 2010 to 2015 and provides up-to date insight for dealmakers with an interest in the immuno-oncology sector. Data and analysis presented in the report is based on the IMS PharmaDeals database, the leading source of deals and alliances information in the life science industry.

Contents

  • Overview of the immuno-oncology drug market by leading companies, therapies and new drugs in late stage development.
  • In-depth analysis of the trends in global M&A and partnering deals by number, development phase and product type.
  • Focused review of partnering deals by stage of development, by deal type and product type.
  • Financial analyses include aggregate and mean total deal values for M&A deals and mean upfront payments, milestones and royalties are presented for partnering deals.
  • A dedicated company analysis section with dealmaking trends of the leading companies and their key deals in immuno-oncology.
  • The report includes an appendix of over 400 immuno-oncology deal records from the IMS PharmaDeals database presented in Excel spreadsheet format.

Key Benefits

  • Negotiate your next immuno-oncology deal with the wealth of IMS PharmaDeals data at your fingertips.
  • Identify who are the most active and least active dealmakers in immuno-oncology.
  • Understand the recent trends in immuno-oncology dealmaking by small and large companies.
  • Find out what deal values have been achieved for immuno-oncology deals including how much are licensees paying in upfront fees and milestones.
  • Access the data source and download immuno-oncology deals to carry out your own analysis.

Table of Contents

EXECUTIVE SUMMARY

CHAPTER 1 MARKET OVERVIEW

  • 1.1 Immuno-Oncology Market
  • 1.2 Current Therapies
  • 1.3 Leading Products in Late-Stage Development
  • 1.4 Market Analysis
  • 1.5 Leading Players
  • 1.6 Summary

CHAPTER 2 OVERALL TRENDS IN IMMUNO-ONCOLOGY

  • 2.1 Deal Intensity

CHAPTER 3 M&A DEALS

  • 3.1 M&A Deal Trends
  • 3.2 M&A Deal Values

CHAPTER 4 PARTNERING DEALS

  • 4.1 Partnering Deal Trends
  • 4.2 Partnering Deals by Total Deal Value
  • 4.3 Partnering Deals by Stage of Development
  • 4.4 PartnerinG Deals By Deal Type
  • 4.5 Partnering Deals by Product Type
  • 4.6 Combination Therapies

CHAPTER 5 COMPANY ANALYSIS: IMMUNO-ONCOLOGY PARTNERING DEALS

  • 5.1 Most Active Dealmakers
  • 5.2 Company Deal Value Analysis

CHAPTER 6 OUTLOOK

APPENDICES

FIGURES

  • Figure 1.1. Market outlook for leading players in immuno-oncology (2014-2020).
  • Figure 2.1. Number of immuno-oncology deals.
  • Figure 2.2. Trends in all deals versus all oncology and immuno-oncology deals.
  • Figure 3.1. M&A deal activity in immuno-oncology.
  • Figure 3.2. M&A deal activity in immuno-oncology compared with overall M&A deal activity in oncology.
  • Figure 3.3. Aggregate total deal values and mean total deal values of immmuno-oncology M&A deals.
  • Figure 3.4. Immuno-oncology M&A deals with total deal values greater than US$100 M.
  • Figure 3.5. Immuno-oncology M&A deal activity by stage of development of the main pipeline asset of the acquisition target.
  • Figure 4.1. Numbers of partnering deals in immuno-oncology between 2010 and 2015.
  • Figure 4.2. Aggregate and mean total deal value for partnering deals.
  • Figure 4.3. Aggregate and mean upfront payment values for partnering deals.
  • Figure 4.4. Number of deals by development stage from 2010 to 2015.
  • Figure 4.5. Deal trends in immuno-oncology deals by development stage.
  • Figure 4.6. Deals by development stage.
  • Figure 4.7. Deal values by stage of development of deals from 2010-2015.
  • Figure 4.8. Upfront payments by stage of development.
  • Figure 4.9. Total numbers of deals by deal type from 2010 to 2015.
  • Figure 4.10. Trends in deal types by year.
  • Figure 4.11. Trends in deals by deal type.
  • Figure 4.12. Number of deals by product type.
  • Figure 4.13. Aggregate and mean total deal values by product type.
  • Figure 4.14. Aggregate and mean upfront payments by product type.
  • Figure 5.1. Most active big pharma companies in immuno-oncology dealmaking.
  • Figure 5.2. Deal activity by big pharma companies in immuno-oncology by year.
  • Figure 5.3. Aggregate and mean TDV of big pharma companies in immuno-oncology.
  • Figure 5.4. Aggregate and mean upfront payments by big pharma companies in immuno-oncology.

TABLES

  • Table 1.1. Select immuno-oncology drugs in late-stage development.
  • Table 1.2. Leading companies in the immuno-oncology sector by sum of analyst consensus forecasts of key brands in 2020.
  • Table 3.1. Top immuno-oncology M&A deals ranked by deal value (2010 to 2015).
  • Table 4.1. Partnering deals with upfront payments greater than US$150 M since 2010.
  • Table 4.2. Selected option deals for immuno-oncology assets.
  • Table 4.3. Antibody deals by highest upfront payments from 2010 to 2015.
  • Table 4.4. Vaccine deals ranked by highest upfront payment from 2010 to 2015.
  • Table 4.5. Cell therapy deals ranked by upfront payment (2010-2015).
  • Table 4.6. Clinical collaborations with immuno-oncology combination therapies.
Back to Top